FDA approval of Biogen Alzheimer’s drug was ‘rife with irregularities,’ congressional report says
Bio Pharma Dive
DECEMBER 30, 2022
An investigation by two House committees concluded the FDA failed to document all its meetings with Biogen, and shifted to consider an accelerated clearance on a “substantially abbreviated timeline.
Let's personalize your content